Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- CRBU
- Price
- 1.55
- Stock movement down
- -0.03 (-1.90%)
- Company name
- Caribou Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 144.88M
- Ent value
- 186.87M
- Price/Sales
- 15.59
- Price/Book
- 1.02
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 18.32%
- 3 year return (CAGR)
- -38.88%
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CRBU does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 15.59 |
| Price to Book | 1.02 |
| EV to Sales | 20.10 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 93.47M |
| EPS (TTM) | -1.68 |
| FCF per share (TTM) | -1.37 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 9.29M |
| Gross profit (TTM) | -21.20M |
| Operating income (TTM) | -158.77M |
| Net income (TTM) | -157.13M |
| EPS (TTM) | -1.68 |
| EPS (1y forward) | -1.35 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -228.08% |
| Operating margin (TTM) | -1708.08% |
| Profit margin (TTM) | -1690.45% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 11.14M |
| Net receivables | 2.07M |
| Total current assets | 155.51M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 36.49M |
| Total assets | 194.98M |
| Accounts payable | 3.80M |
| Short/Current long term debt | 25.46M |
| Total current liabilities | 28.06M |
| Total liabilities | 53.14M |
| Shareholder's equity | 141.84M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -125.64M |
| Capital expenditures (TTM) | 2.09M |
| Free cash flow (TTM) | -127.73M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -110.77% |
| Return on Assets | -80.58% |
| Return on Invested Capital | -108.71% |
| Cash Return on Invested Capital | -88.38% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.57 |
| Daily high | 1.58 |
| Daily low | 1.51 |
| Daily Volume | 629K |
| All-time high | 30.29 |
| 1y analyst estimate | 10.88 |
| Beta | 2.61 |
| EPS (TTM) | -1.68 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 16 Mar 2026 |
Downside potential
Loading...
Downside potential data
| CRBU | S&P500 | |
| Current price drop from All-time high | -94.88% | -1.82% |
| Highest price drop | -97.58% | -56.47% |
| Date of highest drop | 16 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -78.29% | -10.84% |
| Avg time to new high | 104 days | 12 days |
| Max time to new high | 1116 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
144.88M
Marketcap category
Small-cap
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Employees
147
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page